

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: O'Connor, et al

Group No.:

Serial No.: To be assigned

Examiner:

Filed: 16 September 2003

For: 2,6-Substituted Chroman Derivatives Useful as Beta-3 Adrenoreceptor Agonists

CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: 17 September 2003

Monica McGovern

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying copy of PTO form 1449. Copies of the references are not being submitted because they were submitted in a related application, Serial Number 10,131,448.


IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT

The information disclosure statement transmitted herewith is being filed **before** the mailing date of the first Office action on the merits.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,



Susan M. Pellegrino
Attorney for Applicant(s)
Bayer Corporation
400 Morgan Lane
West Haven, CT 06516

Reg. No. 489872

Telephone: (203) 812-6450

Date: 17 September 2003

Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Serial No.	Group Art Unit	Filing Date 16 Sept. 2003	Atty. Docket No. 5062C1		
INFORMATION DISCLOSURE CITATION				Applicant(s): O'Connor, et al					
U.S. PATENT DOCUMENTS									
*		DOCUMENT NO.			DATE MM/DD/YY	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

	U ₀	6	4	6	9	0	3	1	10/22/02	Connell, et al	514	337	12/18/98
	U ₁	6	0	5	1	5	8	6	04/18/00	Ladouceur et al.	514	337	11/23/98
	U ₂	5	9	7	7	1	5	4	11/02/99	Bell et al.	514	394	06/26/97
	U ₃	5	6	6	3	1	9	4	09/02/97	Newshaw	514	456	07/19/96
	U ₄	5	5	6	1	1	4	2	10/01/96	Fisher et al.	514	312	05/22/95
	U ₅	5	5	4	1	1	9	7	07/30/96	Fisher et al.	514	311	03/21/95
	U ₆	5	5	1	6	9	1	7	05/14/96	Djuric et al.	548	525	06/08/94
	U ₇	5	4	5	1	6	7	7	09/19/95	Fisher et al.	546	138	12/15/93
	U ₈	5	3	9	3	7	7	5	02/28/95	Le Baut et al.	514	456	09/07/93
	U ₉	4	6	5	4	3	6	2	03/31/87	Van Lommen et al.	514	452	10/12/84
	U ₁₀	4	6	5	0	8	1	2	03/17/87	Cohen et al.	514	456	01/18/85
	U ₁₁	4	6	4	7	5	7	9	03/03/87	Kabbe et al.	514	456	03/03/97
	U ₁₂	3	8	0	3	1	7	6	04/09/74	Christensen et al.	260	345.2	12/04/72
	U ₁₃	3	7	0	6	7	6	4	12/19/72	Nakanishi et al.	260	327	04/13/70

FOREIGN PATENT DOCUMENTS														
*		DOCUMENT NO.							DATE DD/MM/YY	COUNTRY / NAME	PRIMARY CLASS	SUB- CLASS	TRANSLATION	
													YES	NO
	F ₁	9	9	6	5	8	7	7	23/12/99	WO/Donaldson	C07D	213/80		
	F ₂	9	8	3	2	7	5	3	30/07/98	WO/Mathvink	C07D	417/12		
	F ₃	9	7	4	6	5	5	6	11/12/97	WO/Biftu	C07D	413/10		

EXAMINER	DATE CONSIDERED
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Serial No.	Group Art Unit	Filing Date	Atty. Docket No	
INFORMATION DISCLOSURE CITATION				Applicant(s)				
U.S. PATENT DOCUMENTS								
*		DOCUMENT NO.		DATE MM/DD/YY	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

	F ₄	0	8	0	1	0	6	0	15/10/97	EP / Dow	C07D	209/42		
--	----------------	---	---	---	---	---	---	---	----------	----------	------	--------	--	--

	F ₅	2	7	4	6	3	9	5	26/09/97	FR / Guillaumet	C07D	409/12	X	
	F ₆	9	7	3	5	8	3	5	02/10/97	WO	C07C	217/74	X	
	F ₇	8	1	9	8	8	6	6	06/08/96	JP			X	
	F ₈	9	5	2	9	1	5	9	02/11/95	WO / Fisher	C07D	213/30		
	F ₉	9	5	2	5	1	0	4	21/09/95	WO / Beeley	C07D	405/12		
	F ₁₀	9	4	2	9	2	9	0	22/12/94	WO / Dow	C07D	307/85		
	F ₁₁	0	6	1	1	0	0	3	17/08/94	EP / Fisher	C07C	311/21		
	F ₁₂	0	3	2	8	2	5	1	16/08/89	EP / Caulkett	C07C	103/178		
	F ₁₃	0	0	9	1	7	4	9	19/10/83	EP / Duckworth	C07C	143/78		
	F ₁₄	0	0	7	9	6	3	7	25/05/83	EP / Bantick	C07D	311/24		
	F ₁₅	2	5	1	1	6	4	7	25/09/75	DE / Wirth	C07d	311/22	X	

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)		
R ₁	Hu, B., Ellingboe, J., Gunawan, I., Han, S., Largis, E., Li, Z., Malamas, M., Mulvey, R., Oliphant, A., Sum, F.-W., Tillett, J., Wong, V., "2,4-Thiazolidinediones as Potent and Selective Human β_3 Agonists", Bioorganic & Medicinal Chemistry Letters, <u>11</u> : 757-760 (2001)	
R ₂	Murata, M., Watanabe, S., and Masuda, Y., "Novel Palladium(0)-Catalyzed Coupling Reaction of Dialkoxyborane with Aryl Halides: Convenient Synthetic Route to Arylboronates", J. Org., Chem., <u>62</u> : 6458-6459 (1997)	

EXAMINER	DATE CONSIDERED
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	